Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISA 2022 | What is currently known about AL amyloidosis with cardiac involvement?

Stefano Ricagno • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Stefano Ricagno, PhD, University of Milan, Milan, Italy, shares some insights into AL amyloidosis with cardiac involvement, emphasizing the need to further research and better understand the molecular underpinnings of cardiotoxicity in this disease. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

More from Stefano Ricagno

ISA session highlights: basic research on light chains & cardiotoxicity in amyloidosis 1:56
ISA session highlights: basic research on light chains & cardiotoxicity in amyloidosis
Stefano Ricagno • 6 Sep 2022
The role of protein dynamics and proteolysis in light chain amyloid aggregation 2:51
The role of protein dynamics and proteolysis in light chain amyloid aggregation
Stefano Ricagno • 6 Sep 2022
An insight into organ dysfunction and damage in AL amyloidosis 1:15
An insight into organ dysfunction and damage in AL amyloidosis
Stefano Ricagno • 6 Sep 2022

Related Videos

Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes 2:03
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes
Gareth Morgan • 7 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals